2019

    • September 27, 2021

    Nemaura Medical Announces Commercial Agreement with UK Licensee

    Nemaura has previously placed order for 200,000 CGMs in anticipation of commercial ramp-up Loughborough, England – September 27, 2021...

    Read more
    September 21, 2021

    Nemaura Medical to Present at the Benzinga Healthcare Small Cap Conference

    Loughborough, England – September 21, 2021 (GlobeNewswire) – Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on...

    Read more
    September 17, 2021

    Nemaura Medical announce Professor Osama Hamdy Joins their Advisory Board

    Loughborough, England – September 17, 2021 (GlobeNewswire) – Nemaura Medical, Inc. (NASDAQ: NMRD)(“Nemaura” or the “Company”), a medical technology...

    Read more
    June 30, 2021

    Nemaura Medical Reports Results and Provides Business Update for the Fiscal Year Ended March 31, 2021

    Loughborough, England, June 30, 2021 – Nemaura Medical Inc. (NASDAQ: NMRD) (“Nemaura”), a medical technology company commercializing sugarBEAT®, a...

    Read more
    May 6, 2021

    Nemaura Medical Announces Progress on Listing of sugarBEAT® For Reimbursement in Germany

    Loughborough, England – May 6, 2021 (GlobeNewswire) – Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical...

    Read more
    May 5, 2021

    Nemaura Medical Announces Order for 200,000 sugarBEAT® Sensors

    Based on the success of the soft launch in the U.K., the Company is advancing discussions for joint launches...

    Read more
    April 29, 2021

    Nemaura Medical Issues Letter to Shareholders Following April 28 Shareholder Update Call

    Loughborough, England – April 29, 2021 (GlobeNewswire) – Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical...

    Read more
    April 13, 2021

    Nemaura Medical Launches BEAT®diabetes Smartphone App on Android and iOS Platforms; Begins Pilot Distribution of proBEAT™ Sensors

    Loughborough, England – April 13, 2021 (GlobeNewswire) – Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical...

    Read more
    March 25, 2021

    Nemaura Medical Retains Paul Kennedy as Advisor for International Growth Opportunities and Member of the Executive Advisory Board

    Loughborough, England – March 25, 2021 (GlobeNewswire)– Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic...

    Read more
    March 11, 2021

    Nemaura Medical Announces Submission to German Authorities for Reimbursement of its Glucose Monitoring Device

    Loughborough, England, March 11, 2021 (GLOBE NEWSWIRE) — Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical...

    Read more